193 related articles for article (PubMed ID: 9354617)
1. Nonpolar interactions of thrombin S' subsites with its bivalent inhibitor: methyl scan of the inhibitor linker.
Slon-Usakiewicz JJ; Purisima E; Tsuda Y; Sulea T; Pedyczak A; Féthière J; Cygler M; Konishi Y
Biochemistry; 1997 Nov; 36(44):13494-502. PubMed ID: 9354617
[TBL] [Abstract][Full Text] [Related]
2. Design of P1' and P3' residues of trivalent thrombin inhibitors and their crystal structures.
Slon-Usakiewicz JJ; Sivaraman J; Li Y; Cygler M; Konishi Y
Biochemistry; 2000 Mar; 39(9):2384-91. PubMed ID: 10694407
[TBL] [Abstract][Full Text] [Related]
3. Molecular dynamics simulations of thrombin inhibitors at the S' subsites of thrombin.
Yue SY; Konishi Y
Drug Des Discov; 1994 Jul; 12(1):1-17. PubMed ID: 7578804
[TBL] [Abstract][Full Text] [Related]
4. Potent bivalent thrombin inhibitors: replacement of the scissile peptide bond at P(1)-P(1)' with arginyl ketomethylene isosteres.
Steinmetzer T; Zhu BY; Konishi Y
J Med Chem; 1999 Aug; 42(16):3109-15. PubMed ID: 10447955
[TBL] [Abstract][Full Text] [Related]
5. The methyl group of N(alpha)(Me)Arg-containing peptides disturbs the active-site geometry of thrombin, impairing efficient cleavage.
Friedrich R; Steinmetzer T; Huber R; Stürzebecher J; Bode W
J Mol Biol; 2002 Mar; 316(4):869-74. PubMed ID: 11884127
[TBL] [Abstract][Full Text] [Related]
6. Molecular design and characterization of an alpha-thrombin inhibitor containing a novel P1 moiety.
Malikayil JA; Burkhart JP; Schreuder HA; Broersma RJ; Tardif C; Kutcher LW; Mehdi S; Schatzman GL; Neises B; Peet NP
Biochemistry; 1997 Feb; 36(5):1034-40. PubMed ID: 9033393
[TBL] [Abstract][Full Text] [Related]
7. Variability of the canonical loop conformations in serine proteinases inhibitors and other proteins.
Apostoluk W; Otlewski J
Proteins; 1998 Sep; 32(4):459-74. PubMed ID: 9726416
[TBL] [Abstract][Full Text] [Related]
8. Profiling the structural determinants for the selectivity of representative factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches.
Bhunia SS; Roy KK; Saxena AK
J Chem Inf Model; 2011 Aug; 51(8):1966-85. PubMed ID: 21761917
[TBL] [Abstract][Full Text] [Related]
9. Contribution of lysine 60f to S1' specificity of thrombin.
Rezaie AR; Olson ST
Biochemistry; 1997 Feb; 36(5):1026-33. PubMed ID: 9033392
[TBL] [Abstract][Full Text] [Related]
10. Structure-based understanding of ligand affinity using human thrombin as a model system.
Nienaber VL; Mersinger LJ; Kettner CA
Biochemistry; 1996 Jul; 35(30):9690-9. PubMed ID: 8703940
[TBL] [Abstract][Full Text] [Related]
11. New bivalent thrombin inhibitors with N(alpha)(methyl)arginine at the P1-position.
Steinmetzer T; Batdordshjin M; Pineda F; Seyfarth L; Vogel A; Reissmann S; Hauptmann J; Stürzebecher J
Biol Chem; 2000 Jul; 381(7):603-10. PubMed ID: 10987367
[TBL] [Abstract][Full Text] [Related]
12. In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design.
Costanzo MJ; Almond HR; Hecker LR; Schott MR; Yabut SC; Zhang HC; Andrade-Gordon P; Corcoran TW; Giardino EC; Kauffman JA; Lewis JM; de Garavilla L; Haertlein BJ; Maryanoff BE
J Med Chem; 2005 Mar; 48(6):1984-2008. PubMed ID: 15771442
[TBL] [Abstract][Full Text] [Related]
13. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
14. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes.
Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T
J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396
[TBL] [Abstract][Full Text] [Related]
15. Characterization of the P2' and P3' specificities of thrombin using fluorescence-quenched substrates and mapping of the subsites by mutagenesis.
Le Bonniec BF; Myles T; Johnson T; Knight CG; Tapparelli C; Stone SR
Biochemistry; 1996 Jun; 35(22):7114-22. PubMed ID: 8679538
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the complex of human alpha-thrombin and nonhydrolyzable bifunctional inhibitors, hirutonin-2 and hirutonin-6.
Zdanov A; Wu S; DiMaio J; Konishi Y; Li Y; Wu X; Edwards BF; Martin PD; Cygler M
Proteins; 1993 Nov; 17(3):252-65. PubMed ID: 8272424
[TBL] [Abstract][Full Text] [Related]
17. Hirunorms are true hirudin mimetics. The crystal structure of human alpha-thrombin-hirunorm V complex.
De Simone G; Lombardi A; Galdiero S; Nastri F; Della Morte R; Staiano N; Pedone C; Bolognesi M; Pavone V
Protein Sci; 1998 Feb; 7(2):243-53. PubMed ID: 9521099
[TBL] [Abstract][Full Text] [Related]
18. Bovine thrombin complexed with an uncleavable analog of residues 7-19 of fibrinogen A alpha: geometry of the catalytic triad and interactions of the P1', P2', and P3' substrate residues.
Martin PD; Malkowski MG; DiMaio J; Konishi Y; Ni F; Edwards BF
Biochemistry; 1996 Oct; 35(40):13030-9. PubMed ID: 8855938
[TBL] [Abstract][Full Text] [Related]
19. Rational design and selection of bivalent peptide ligands of thrombin incorporating P4-P1 tetrapeptide sequences: from good substrates to potent inhibitors.
Su Z; Vinogradova A; Koutychenko A; Tolkatchev D; Ni F
Protein Eng Des Sel; 2004 Aug; 17(8):647-57. PubMed ID: 15358856
[TBL] [Abstract][Full Text] [Related]
20. Peptidyl beta-homo-aspartals (3-amino-4-carboxybutyraldehydes): new specific inhibitors of caspases.
Bajusz S; Fauszt I; Németh K; Barabás E; Juhász A; Patthy M; Bauer PI
Biopolymers; 1999; 51(1):109-18. PubMed ID: 10380358
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
